Publication date: Jun 19, 2024
The COVID-19 pandemic has brought significant changes in managing of patients with rheumatoid arthritis. Rituximab-treated patients were more susceptible to severe infection. This required a “switch” to another genetically engineered drug in the patients with high risk of adverse COVID-19. In this study, we assessed the severity of immune response to SARS-CoV-2 antigens in rituximab-treated patients with rheumatoid arthritis vaccinated with the combined vector vaccine Gam-COVID-Vac. Insufficient formation of the humoral response and a high level of T-cell response to SARS-CoV-2 antigens in this group of patients were revealed. An imbalance of cellular and humoral response may play a role in more severe COVID-19 in rituximab-treated patients with rheumatoid arthritis.
| Concepts | Keywords |
|---|---|
| High | rheumatoid arthritis |
| Play | rituximab |
| Rheumatoid | SARS-CoV-2 |
| Rituximab | vaccination |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | cell |
| disease | IDO | humoral immune response |
| drug | DRUGBANK | Rituximab |
| disease | MESH | Rheumatoid Arthritis |
| pathway | KEGG | Rheumatoid arthritis |
| disease | VO | vaccinated |
| disease | VO | vaccine |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | infection |
| disease | IDO | immune response |
| disease | VO | vaccination |